All In Biotech

Drug Trial Radar · NCT04115306

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Ph 1/1b/2 Multicenter, Open-Label, FIH Dose Esc & Dose Exp Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients With Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

61

Planned (sponsor's estimate)

Start

Nov 14, 2019

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Phoenix Molecular DesignsIndustry
Sponsor type
Industry
First posted
Oct 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.

Conditions

  • Metastatic Breast Cancer

Interventions

  • PMD-026Drug

    Investigational Drug

  • fulvestrantDrug

    SERDs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of PMD-026 in combination with fulvestrant in patients with HR+/HER2- previously treated breast cancerTime frame: 6 weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • City of Hope

    Duarte, California

  • City of Hope Orange County, Lennar

    Irvine, California

  • University of California, Los Angeles (UCLA)

    Los Angeles, California

  • Moffitt Cancer Center

    Tampa, Florida

  • City of Hope Chicago

    Zion, Illinois

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Profound Research

    Farmington Hills, Michigan

  • Ohio State University

    Columbus, Ohio

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.